# Fortrea Acquires Worldwide Clinical Trials Division

> Fortrea completes $45m acquisition of Worldwide Clinical Trials' early phase services to boost clinical research capacity.
- Title: Fortrea Acquires Worldwide Clinical Trials Division | Shortify
- Summary: Fortrea completes $45m acquisition of Worldwide Clinical Trials' early phase services to boost clinical research capacity. Fortrea acquired Worldwide…
- Keywords: fortrea, worldwide clinical trials, early phase services, clinical research, crot, nasa, glp, gcp, bioanalytical laboratory, clinical pharmacology, biospecimen storage, seattle
- Source: Financialpost — https://financialpost.com/globe-newswire/fortrea-completes-acquisition-of-the-early-phase-services-division-from-worldwide-clinical-trials
- Read time: 1 min
- Topics: fortrea, worldwide clinical trials, early phase services, clinical research, crot, nasa, glp, gcp, bioanalytical laboratory, clinical pharmacology, biospecimen storage, seattle
## Fortrea completes acquisition
Fortrea completed acquisition of Worldwide Clinical Trials' early phase services division for $45 million in an all-cash transaction.
## Adds Texas facilities
Adds 60,000-square-foot GLP-compliant lab in Austin, Texas; 200-bed GCP-compliant unit in San Antonio, Texas; and biospecimen storage in Pflugerville, Texas.
## Expands global capacity
Expands early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities.
## Enhances platform integration
Reduces operational handoffs between clinical and bioanalytical functions to improve study execution and data quality.
## Strengthened platform
Strengthens end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation.
## Continuity agreements
Entered strategic alliance agreement to support continuity of operations, study delivery and client support during transition.
## Key takeaway

Fortrea acquired Worldwide Clinical Trials' early phase services division for $45 million, expanding its global clinical development capacity to over 570 beds and adding bioanalytical capabilities.